Specialty chemistry solutions giant Lubrizol will spotlight a major expansion of its global medical device manufacturing footprint at World Health Expo (WHX) Dubai, taking place February 9–12, 2026. The company's exhibits underscore its push to accelerate medical device innovation worldwide.
Central to that expansion is a new contract manufacturing operation in India, including a state-of-the-art medical manufacturing facility in Chennai, Tamil Nadu, scheduled to open in mid-2026. The site will significantly enhance Lubrizol’s ability to serve global medical device customers with high-precision components produced closer to key growth markets.
The Chennai facility will manufacture high-quality medical tubing for neurovascular and cardiovascular applications, including balloon catheters and other minimally invasive devices. Production will leverage Lubrizol’s advanced medical-grade thermoplastic polyurethane (TPU) and other biocompatible engineered polymers, supporting applications across electrostimulation, cardiovascular, neurovascular, and related technologies.
Key capabilities at the site will include single- and multi-lumen precision extrusion of TPU, Nylon, Pebax and other engineered thermoplastics, along with tri-layer tubing, balloon tubing, and braiding—broadening Lubrizol’s end-to-end manufacturing offering for complex medical devices.
“We are strengthening our presence in India with strategic investments in local manufacturing, R&D, and technical capabilities,” said Mittal Shah, Business Head at Lubrizol. “These investments address our customers’ need for biocompatible, high-performance materials and advanced solutions that enable medical device innovation in India and globally.”
Lubrizol operates more than 100 manufacturing facilities worldwide and employs over 7,000 people globally.
The India, Middle East, and Africa (IMEA) region is one of Lubrizol’s fastest-growing geographies, serving dynamic markets with advanced solutions in additives, engineered materials, coatings, and life sciences.
